Career Panel 2014
Chief Executive Officer (CEO) of IndUS Pharmaceuticals
Chairman and CEO of Aerie Pharmaceuticals
Director, Biopharma Project Management, Bristol Myers Squibb Co., Princeton, NJ
GM and Clinical Director, West Virginia University’s Clinical & Pharmacologic Research Center (CPRC);
Associate Professor of Pharmaceutical Systems and Compliance, WVU School of Pharmacy
Dr. Chaturvedi currently maintains multiple roles as the Chief Executive Officer of IndUS Pharmaceuticals and the Chief Scientific Officer of Napo Pharmaceuticals. He is a serial entrepreneur and has been the founder or co-founder of Oceanyx, IndUS and Scion Pharmaceuticals. Dr. Chaturvedi is or has previously served on the Boards of Scion, IndUS, Oceanyx, FuelEd, Sindu and TiE Boston. IndUS Pharmaceuticals (and its Indian subsidiary Sindu Research Laboratories) is a cross-border pharmaceutical company focused on the treatment of cancer, diabetes and infectious diseases. IndUS was acquired by San Francisco headquartered and London Stock Exchange listed, Napo Pharmaceuticals in 2007. IndUS was subsequently spun-out by Dr. Chaturvedi in 2010 and is now privately held. Oceanyx Pharmaceuticals focuses on the discovery of new drugs from marine bacteria for the treatment of cancer, inflammation and bone disorders. Scion Pharmaceuticals focused on the discovery of drugs for neuropathic pain and atrial fibrillation and was sold to Wyeth in 2005. Prior to founding Oceanyx, IndUS and Scion Pharmaceuticals, Dr. Chaturvedi, spent several years at Vertex Pharmaceuticals as the Head of Lead Evaluation, where he participated in the discovery and development of novel antiviral and anti-inflammatory drugs. Prior to Vertex, he was in the preclinical group at Alkermes, which focused on delivery of therapeutic agents to the CNS. Dr. Chaturvedi was in the Product Development group at Parke-Davis/Warner-Lambert Company (now Pfizer), where he was involved in the development of new drugs for the treatment of oncology, epilepsy, pain and cognition. Dr. Chaturvedi holds a Ph.D. in Pharmaceutical Sciences from West Virginia University and a Bachelor’s in Pharmacy from the University of Bombay.
Dr. Vicente Anido, Jr., grew up believing anything is possible. His father instilled the values of hard work and a can-do attitude. Today, Dr. Anido is a highly respected ophthalmology industry veteran and leader with more than 37 years of multinational general management experience in the healthcare field, including broad exposure in prescription and non-prescription pharmaceuticals, medical devices, diagnostics and biologics. He is a multifaceted leader, having excelled in managing both large and small companies – public and private. Dr. Anido’s substantial experience and solid reputation for building focused, results-oriented teams has served him well in successfully executing multiple private and public financings, including IPO’s and taking companies private. He has served on multiple boards of directors of public, private and non-profit companies.
Dr. Anido, a native of Morgantown, currently serves as Chariman and CEO of Aerie Pharmaceuticals, Inc., a publicly traded (NASDAQ) clinical stage pharmaceutical company focused on developing products to treat glaucoma. The company has offices in Bedminster, NJ; Research Triangle Park, NC; and Newport Beach, CA.
From 2001 to 2012, he was president, CEO and a director of ISTAPharmaceuticals, which was acquired by Bausch & Lomb. Prior to this, Dr. Anido served as general partner of Windamere Venture Partners. He also has served as president and CEO of CombiChem, Inc., a biotechnology company, and was president of the Americas Region of Allergan, Inc., a specialty pharmaceutical company focusing on ophthalmology, dermatology and neuromuscular indications. Prior to Allergan, Dr. Anido held management positions at Marion Laboratories and Marion Merrell Dow, Inc.
Dr. Anido serves on the Board of Directors of NiCox, QLT, Inc. and Depomed, Inc. Both are NASDAQ listed pharmaceutical companies. He also serves as a strategic advisor to CheckedUP, a mobile-health management software platform and application that empowers patients to manage their surgical process.
Dr. Anido, who was born in Havana, Cuba, received a bachelor’s degree in pharmacy (‘75) and a master’s degree in pharmacy administration (‘78) from West Virginia University and a doctorate in pharmacy administration from the University of Missouri-Kansas City. In 2013 he received an honorary doctorate of science from the WVU School of Pharmacy.
Dr. Knight-Trent received her B.A. in Biology in 1996 and Pharm.D. in 2000 from West Virginia University. She is a registered pharmacist in West Virginia. While attending WVU she worked in the laboratory of Dr. Michael Miller assisting with breast cancer cell culture research. This sparked her interest in oncology and specifically drug development. Following graduation, she was a post-doctoral research fellow at Roche Pharmaceuticals and Rutger’s University with the external component conducted at the FDA’s Center for Drug Evaluation Oncology Division. She is a supporter of the WVU pharmacy school with the Autumn Grace Trent endowed scholarship.
In 2001, she joined Roche Pharmaceuticals as a US regulatory liaison with FDA and worked on the various stages of development of drugs and biologics from first in human studies to post-approval in multiple therapeutic areas (eg, oncology, neuroscience, immunology, and virology). Most notably was the joint negotiation with colleagues of the approval for new drug application of Fuzeon (enfuvirtide) for HIV.
In 2006, she joined Bristol Myers Squibb to pursue her passion to bring new medicines to cancer patients. She was the Global Regulatory Leader and US Liaison and led negotiations for the successful approval of Ixempra (ixabepilone) for breast cancer in the US. Following the approval in 2007, she was asked to be the Global Regulatory Leader and US Liaison for Yervoy (ipilimumab). This was a new challenge in the field of immuno-oncology. She led the negotiations for the successful approval of Yervoy in US, EU and multiple other countries. She also led within the regulatory department the integration of multiple immuno-oncology products from Medarex following acquisition. In 2011, she moved with her family to Paris, France, for a 1.5 year assignment supervising the BMS regulatory offices in over 20 countries. In late 2012, she relocated to Seattle, Washington, for the role of Senior Director and Head of Regulatory at Zymogenetics, a subsidiary of BMS. She also was responsible for BMS regulatory business operations on multiple early development activities including leading the creation of a new guide to early development with a cross-functional team in multiple countries. In 2013, she relocated to the BMS headquarters in Princeton, New Jersey, to pursue a career development opportunity in Biopharma Project Management focused on the development and then transition of diabetes drugs to AstraZeneca.
He received his Ph.D. in pharmacology in 1975 from The Ohio State University with a major research interest in behavioral effects and biochemical mechanisms of central nervous system stimulants.
He continued his research and teaching career in the Division of Pharmacology and Toxicology at the College of Pharmacy, The University of Texas at Austin from 1975 until May, 1996. During that period, his research interests focused on CNS stimulants and he studied the mechanism by which these agents induce a "reverse tolerance" and thereby elicit the neurochemical basis for "stimulant-induced psychosis".
Since 1990, Dr. Riffee has concentrated his research and teaching efforts in the area of educational technology and its utility in the classroom and online to serve both near and distant sites. He is known nationally as well as internationally as an innovator in the area of teaching and the use of video (live and streaming) and computer-based presentation technology as well as the use of the computer as a learning tool. He has also been involved in the design and installation of electronic classrooms providing connectivity for the student with instructors wherever they may be located. He has worked extensively with business partners who provide hosting technology and streaming video services throughout the world.
June 1, 1996, Dr. Riffee was named Dean and Professor, College of Pharmacy, The University of Florida. He continued his interest in educational technology as he pursued his work as an administrative officer of the University. In 2002, Dr. Riffee and the faculty expanded the College’s outreach to add three campuses in Jacksonville, Orlando and St. Petersburg resulting in the admission of more than double the number of students. This was accomplished through the leverage of the work of the world-class faculty with the use of state-of-the-art technology. Currently, the College has over 1200 first professional degree students. In addition, the College expanded its post baccalaureate Pharm.D. program and has graduated over 2500 students since 1998. Dr. Riffee also fostered the development of online masters degree programs in Drug Policy and Regulation, Pharmacoepidemiology, Forensic Sciences and others resulting in a graduate program of over 400 students across the country. From 2001 until 2006, Dr. Riffee served as Associate Provost for Distance, Continuing and Executive Education for the University, helping to expand the online programs for other Colleges on campus.
Over the years, Dr. Riffee has engaged in work with colleagues around the world discussing ways to extend education to various groups within Europe (Germany and Italy), Africa (South Africa), Asia (China and Thailand), the Middle East (Saudi Arabia and UAE), India and South America (Brazil, Ecuador, Peru).
In 2013, Dr. Riffee began serving as Speaker of the House of the American Pharmacist Association and serves as one of the organization’s Trustees. The major emphasis of the Association at present is the objective of pursing “provider status” for pharmacists.
Dr. Riffee retired as Dean Emeritus in 2013 and now lives with his wife Judy in the mountains of West Virginia, their home state.
Dr. Allie Karshenas
Dr. Karshenas is the GM and Clinical Director of West Virginia University’s Clinical & Pharmacologic Research Center (CPRC) as well as an Associate Professor of Pharmaceutical Systems and Compliance in the School of Pharmacy. Dr. Karshenas came to WVU from Abbott Laboratories where he functioned as their Director of patient Services and the Privacy Officer.
Dr. Karshenas received his doctorate degree from the University of Southern Mississippi in Laboratory Medicine with emphasis in infectious diseases. He has carried out his Diagnostic internship at St. Thomas Hospital in Nashville, TN and his Post-doctorate at Gulf Coast Research Laboratories in Biloxi, MS.
Shortly after his post-graduate work, Dr. Karshenas joined Roche Diagnostics where he functioned as the Division technical Director for over 5 years. .Dr. Karshenas led the Global Clinical and Technical Engineering functions for Becton Dickinson (BD) for 5 years before he joined Thermo-Fisher as their Vice-President of Clinical Operations in Molecular Genetics and Pharmacogenomics.
In 2006 Dr. Karshenas Joined Siemens/ Drager Acute Care Division to lead their Clinical and Application Engineering functions as their Vice President of Clinical Operations. Subsequently he joined a global Contract Research Organization, Kendle International as their Clinical Director of Operations for Phase-I Clinical Pharmacology.
Dr. Karshenas has a diverse clinical and technical expertise with highly specialized leadership skills in organizational development. In his 25 years of industry careers, he has had experience with STARS (Start-ups, Turn-around, Realignments, and Sustaining Success) organizations. He is a Six-Sigma Black Belt professional with certifications in Lean-Sigma operations.